Follow us on Facebook!
Follow us on Twitter!
Follow us on Youtube!
Recent news
News archive

The European Hematology Association (EHA) and European Society for Blood and Marrow Transplantation (EBMT) held the first European CAR T Cell Meeting together in Paris on February 14-16, 2019.

Chimeric Antigen Receptor T-cell therapy (CAR-T) is revolutionizing the field of hematologic malignancies and has the potential to achieve cure for a number of dreadful diseases. The recent approvals of the first CAR T Cell treatments in Europe provide a great opportunity to fight hematologic malignancies, but also poses serious challenges given the peculiar nature of the treatment.

This 1st European CAR-T workshop was a great opportunity to exchange experience and knowledge with the key opinion leader in the CAR-T field and to train physicians and nurses from all over Europe. This important scientific meeting was co-chaired by the CARAMBA coordinator Dr. Michael Hudecek.

The Horizon 2020 CARAMBA project is using the revolutionary CAR-T cell technology. Through strategic collaboration with a wide-range of stakeholders, including Myeloma Patients Europe, the consortium aims to ensure the streamlined transition of CAR-T from the laboratory through to myeloma patients in the clinic.

Within CARAMBA, a phase I/II immunotherapy clinical trial will be conducted with patient-derived T-cells that are engineered to express a synthetic chimeric antigen receptor (CAR) specific for the myeloma antigen SLAMF7.

 

Members of the CARAMBA project consortium explain in this video the role of CAR-T cells in myeloma and highlights discussed in this scientific meeting.

 

 

Find more information on the Horizon2020 CARAMBA project in this video recorded in English and translated into four additional languages: French, German, Spanish and Italian

For further information, please visit the Horizon2020 website: https://www.caramba-cart.eu/

Leave a Reply

Your email address will not be published. Required fields are marked *